| Assessment Status |
Rapid Review Complete |
| HTA ID |
24030 |
| Drug |
Pegylated Liposomal irinotecan |
| Brand |
Onivyde® |
| Indication |
Liposomal irinotecan in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. |
| Rapid review commissioned |
24/07/2024 |
| Rapid review completed |
22/08/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pegylated liposomal irinotecan compared with the current standard of care. |
